Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 7/20 | 0.38 |
| ▸ | ABL1 | P00519 | 4/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 3/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4721937 | 0.91 | ADK (0.37) | ADKABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL5250424 | 0.89 | KDR (0.38) | ADKKDR | |
| SCHEMBL4718135 | 0.88 | ADK (0.48) | ADKABL1FFAR1GRM5RET | |
| SCHEMBL3581185 | 0.84 | LCK (0.43) | FFAR1KDRGRM5ASIC3NPSR1 | |
| SCHEMBL5250427 | 0.81 | NPC1 (0.37) | ADKKDRRET | |
| SCHEMBL27649219 | 0.79 | LCK (0.39) | ADKABL1FFAR1KDRGRM5 | |
| SCHEMBL5302989 | 0.78 | ABL1 (0.45) | ADKABL1CA12CA1CA2 | |
| SCHEMBL27669464 | 0.76 | ADK (0.33) | ADKABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL27669462 | 0.76 | ADK (0.39) | ADK | |
| SCHEMBL4719226 | 0.75 | KDR (0.58) | ABL1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | ADK 247/4885ABL1 81/4885PIK3CD 2592/4885 |
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | ADK 252/4885ABL1 36/4885PIK3CD 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.